177 related articles for article (PubMed ID: 15737773)
1. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.
Cassidy WM; Jones G; Williams K; Deforest A; Forghani B; Virella G; Venters C
J Adolesc Health; 2005 Mar; 36(3):187-92. PubMed ID: 15737773
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
Black S; Friedland LR; Schuind A; Howe B;
Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
[TBL] [Abstract][Full Text] [Related]
4. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.
Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N
Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
13. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
[TBL] [Abstract][Full Text] [Related]
14. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
15. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.
Hesley TM; Reisinger KS; Sullivan BJ; Jensen EH; Stasiorowski S; Meechan C; Chan CY; West DJ;
Pediatr Infect Dis J; 2004 Mar; 23(3):240-5. PubMed ID: 15014300
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
[TBL] [Abstract][Full Text] [Related]
17. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium.
Theeten H; Hutse V; Hens N; Yavuz Y; Hoppenbrouwers K; Beutels P; Vranckx R; Van Damme P
Epidemiol Infect; 2011 Apr; 139(4):494-504. PubMed ID: 20587123
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.
Gatchalian S; Tabora C; Bermal N; Leboulleux D; Desauziers E
Am J Trop Med Hyg; 2004 Mar; 70(3):273-7. PubMed ID: 15031516
[TBL] [Abstract][Full Text] [Related]
20. Adult immunization.
Treat Guidel Med Lett; 2006 Jul; 4(47):47-54. PubMed ID: 16785849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
